Brineura (cerliponase alfa) (Cerliponase Alfa KIT)

Brineura (cerliponase alfa) is an FDA-approved orphan drug developed by BioMarin Pharmaceutical Inc. for the treatment of Ceroid Lipofuscinosis Type 2 (CLN2), commonly known as Batten disease. It represents a breakthrough in neurology for this rare, progressive lysosomal storage disorder affecting children.

Pack Size

1 KIT in 1 CARTON (68135-811-02) * 5 mL in 1 VIAL, GLASS (68135-500-00) * 5 mL in 1 VIAL, GLASS

Manufacturer / TM Owner

BioMarin Pharmaceutical Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Brineura is indicated for the treatment of CLN2 disease, a rare inherited neurodegenerative lysosomal storage disorder that typically manifests in early childhood with progressive vision loss, seizures, cognitive decline, and motor deterioration. The drug is administered via intraventricular infusion directly into the cerebrospinal fluid, allowing direct delivery to the central nervous system. Brineura contains cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (TPP1) enzyme that addresses the underlying enzyme deficiency characteristic of CLN2 disease. The target patient population includes children diagnosed with CLN2 disease, particularly those in early stages of the disease course. By replacing the deficient TPP1 enzyme, Brineura aims to slow the progression of neurological decline, preserve cognitive and motor function, and improve quality of life in affected children.

Side Effects

Common adverse events associated with Brineura include headache, fever, vomiting, and irritability, typically occurring post-infusion. Serious adverse events include meningitis, ventriculitis, catheter-related infections, and increased intracranial pressure. Immune-related reactions and hypersensitivity responses have been documented. Patients require regular monitoring including neurological assessments, ophthalmologic evaluations, and imaging studies to assess disease progression and treatment response. Cerebrospinal fluid parameters and signs of infection or inflammation warrant close surveillance given the intraventricular administration route.

Precautions & Warnings

Brineura is contraindicated in patients with active infections or uncontrolled seizure disorders. Caution is warranted in patients with compromised immune function or bleeding disorders. The drug has not been studied in pregnant women; use during pregnancy should only occur if benefits justify risks. Pediatric patients represent the primary population, though careful patient selection based on disease stage is essential. Hepatic and renal impairment do not directly contraindicate use, but overall clinical status must be carefully evaluated. Patients must have adequate ventricular access and be able to tolerate intraventricular procedures.

Avoid Interactions

Limited drug-drug interaction data exists for Brineura due to its intraventricular administration and enzymatic nature. Concurrent use of other CNS-active medications should be evaluated carefully. Immunosuppressive agents may theoretically affect immune responses to the enzyme replacement therapy. No significant food or substance interactions have been identified. Patients receiving anticoagulants or antiplatelet agents require monitoring due to potential bleeding risk at catheter sites. Healthcare providers should maintain updated medication profiles and consult specialized neurology resources.

Frequently Asked Questions

Brineura is used to treat Ceroid Lipofuscinosis Type 2 (CLN2), a rare inherited neurodegenerative disease also known as Batten disease. It is administered directly into the cerebrospinal fluid via intraventricular infusion to replace the deficient TPP1 enzyme and slow disease progression.

Brineura is administered as an intraventricular infusion, meaning it is delivered directly into the cerebrospinal fluid through a surgically placed catheter or ventricular access device. This route allows the enzyme to reach the central nervous system effectively.

Common side effects include headache, fever, vomiting, and irritability. More serious adverse events can include meningitis, ventriculitis, and catheter-related infections. Patients require close medical monitoring during and after treatment.

Brineura is manufactured by BioMarin Pharmaceutical Inc., a biopharmaceutical company specializing in rare genetic diseases.

Yes, Brineura received FDA orphan drug designation for the treatment of CLN2 disease. This status recognizes its development for a rare disease affecting a small patient population and provides regulatory incentives to support drug development.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.